This series of 4 podcasts will include discussions with expert leaders in melanoma. The content will focus on evaluating the use of immune checkpoint inhibitors in Stage II, Stage III, and Stage IV melanoma, understanding and overcoming resistance to anti- programmed cell death protein 1 (PD-1) immunotherapy, advances in the treatment and outcomes of patients with brain metastases, and the use of adjuvant and neoadjuvant treatment approaches.